Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids

Fig. 1

CDK12 and CDK13 alterations in Ovarian Serous Cystadenocarcinoma. a, b Oncoplots showing the distribution of mutations in CDK12, CDK13, MYC and selected DDR genes in ovarian serous cystadenocarcinoma patients analyzed in the Pancancer Atlas project of TCGA. The Tumor Mutational Burden (TMB) plot shows the frequency of mutations for each tumor sample. The lower plots show the type of mutation fpr each indicated gene in each tumor sample. The orizontal bar graphs (right side) report the number of samples mutated. c, Pearson’s correlation plot of the expression levels of CDK12 and CDK13 transcripts, data from 375 ovarian serous cystadenocarcinoma patients deposited in the Pancancer Atlas project of TCGA. Pearson’s correlation coefficient (r) and P-value are reported. d, e Kaplan–Meier curves comparing the overall survival of patients described above with concomitant high (red) or low (blue) expression of MYC, CDK12, CDK13 transcripts (d) or with high (red) or low (blue) expression of MYC transcript (e)

Back to article page